<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To explore therapeutic efficacy of <z:chebi fb="5" ids="50113">androgens</z:chebi> and low dose <z:hpo ids='HP_0000001'>all</z:hpo>-trans <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (ATRA) for <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) patients, 55 patients of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were observed, including 41 cases of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), 11 cases of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), 2 cases of <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t) and 1 case of <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloic-monocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>These patients received <z:chebi fb="1" ids="4315">danazol</z:chebi> (600 mg/day) or stanazol (6 mg/day) and ATRA (10 mg/day) for at least 3 months </plain></SENT>
<SENT sid="2" pm="."><plain>The results showed that according to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> international working group response criteria, at the end of three months,complete remission (CR) was seen in 1 patient, partial remission (PR) was found in 2 patients </plain></SENT>
<SENT sid="3" pm="."><plain>Hematologic improvement: major response (MaR) were seen in 15 patients, minor response (MiR) were seen in 4 patients </plain></SENT>
<SENT sid="4" pm="."><plain>The total response rate was 35.8% </plain></SENT>
<SENT sid="5" pm="."><plain>In conclusion, <z:chebi fb="1" ids="4315">danazol</z:chebi> or stanazol in combination with low dose ATRA are partialy effective in therapy for patients with low-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
</text></document>